ELCC 2023 | Current and future approaches of immunotherapy for NSCLC

Ana Laura Ortega Granados, MD, University Hospital of Jaén, Jaén, Spain, discusses the landscape of non-squamous non-small cell lung cancer (NSCLC) immunotherapy. Currently, chemotherapy and combination immunotherapy are standard treatment practices but the increasing amount of positive data for the use of dostarlimab and pembrolizumab anti-PD1 drugs is an exciting prospect. This interview took place at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.